CN1663449A - A health food with protective effect on chemical liver damage - Google Patents
A health food with protective effect on chemical liver damage Download PDFInfo
- Publication number
- CN1663449A CN1663449A CN2005100333975A CN200510033397A CN1663449A CN 1663449 A CN1663449 A CN 1663449A CN 2005100333975 A CN2005100333975 A CN 2005100333975A CN 200510033397 A CN200510033397 A CN 200510033397A CN 1663449 A CN1663449 A CN 1663449A
- Authority
- CN
- China
- Prior art keywords
- liver
- health food
- protective effect
- chemical liver
- chemical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000126 substance Substances 0.000 title claims abstract description 25
- 206010067125 Liver injury Diseases 0.000 title claims abstract description 23
- 231100000234 hepatic damage Toxicity 0.000 title claims abstract description 17
- 230000008818 liver damage Effects 0.000 title claims abstract description 17
- 235000013402 health food Nutrition 0.000 title claims description 26
- 230000001681 protective effect Effects 0.000 title claims description 10
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 24
- 239000000843 powder Substances 0.000 claims abstract description 14
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims abstract description 12
- 235000010413 sodium alginate Nutrition 0.000 claims abstract description 12
- 239000000661 sodium alginate Substances 0.000 claims abstract description 12
- 229940005550 sodium alginate Drugs 0.000 claims abstract description 12
- 229960003080 taurine Drugs 0.000 claims abstract description 12
- 231100000753 hepatic injury Toxicity 0.000 claims abstract description 6
- 239000002994 raw material Substances 0.000 claims description 12
- 239000008187 granular material Substances 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 5
- 239000003826 tablet Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 208000019425 cirrhosis of liver Diseases 0.000 abstract description 11
- 230000006870 function Effects 0.000 abstract description 9
- 235000013305 food Nutrition 0.000 abstract description 5
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 abstract 2
- 210000003494 hepatocyte Anatomy 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 description 30
- 230000000694 effects Effects 0.000 description 20
- 210000005229 liver cell Anatomy 0.000 description 19
- 239000003814 drug Substances 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 10
- 231100000331 toxic Toxicity 0.000 description 10
- 230000002588 toxic effect Effects 0.000 description 10
- 238000000034 method Methods 0.000 description 9
- 229940079593 drug Drugs 0.000 description 7
- 239000003925 fat Substances 0.000 description 7
- 208000006454 hepatitis Diseases 0.000 description 7
- 230000006378 damage Effects 0.000 description 6
- 208000019423 liver disease Diseases 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 6
- 208000004930 Fatty Liver Diseases 0.000 description 5
- 206010019708 Hepatic steatosis Diseases 0.000 description 5
- 208000010706 fatty liver disease Diseases 0.000 description 5
- 230000008929 regeneration Effects 0.000 description 5
- 238000011069 regeneration method Methods 0.000 description 5
- 231100000240 steatosis hepatitis Toxicity 0.000 description 5
- 206010008909 Chronic Hepatitis Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 231100000283 hepatitis Toxicity 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 3
- 108010082126 Alanine transaminase Proteins 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000005251 gamma ray Effects 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 231100000987 absorbed dose Toxicity 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000001914 calming effect Effects 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 238000003912 environmental pollution Methods 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 210000003712 lysosome Anatomy 0.000 description 2
- 230000001868 lysosomic effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000000419 Chronic Hepatitis B Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 206010019755 Hepatitis chronic active Diseases 0.000 description 1
- 206010019759 Hepatitis chronic persistent Diseases 0.000 description 1
- 206010019837 Hepatocellular injury Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000019280 Pancreatic lipases Human genes 0.000 description 1
- 108050006759 Pancreatic lipases Proteins 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000002390 cell membrane structure Anatomy 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000005429 filling process Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 235000021268 hot food Nutrition 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 231100000849 liver cell damage Toxicity 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 229940116369 pancreatic lipase Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
技术领域technical field
本发明涉及一种对化学性肝损伤有保护作用的保健食品，尤其涉及一种以海洋生物提取物为原料制备的对化学性肝损伤有保护作用的保健食品。The invention relates to a health food with protective effect on chemical liver damage, in particular to a health food with protective effect on chemical liver damage prepared from marine organism extracts.
背景技术Background technique
我国是肝炎的高发区，以乙肝为例，我国曾受过乙型肝炎病毒感染的人群高达七亿多，其中1.2亿多人终生携带病毒，其中3000万人将会向肝硬化演变，而肝硬化大约有3％-5％会发展成为肝癌。持续的慢性肝实质炎症、坏死可导致肝脏持续不断的纤维增生而形成肝纤维化，并向肝硬化发展。近年来由于生活水平提高，饮食结构变化及预防保健措施相对滞后，脂肪肝发病率仍在上升，且发病率年龄越来越小。另一方面社会环境的变化，带来新的合成药剂及化学药品的增加，甚至带来环境的污染及其公害，它和酒精中毒一样，是产生化学性肝损伤的直原因。肝病严重降低了病人的生活质量，缩短了病人的寿命。my country is a high-incidence area of hepatitis. Taking hepatitis B as an example, there are more than 700 million people who have been infected by hepatitis B virus in my country, of which more than 120 million people carry the virus for life, and 30 million of them will develop into liver cirrhosis, and liver cirrhosis About 3%-5% will develop into liver cancer. Sustained chronic inflammation and necrosis of the liver parenchyma can lead to continuous fibrous hyperplasia in the liver, forming liver fibrosis, and developing to liver cirrhosis. In recent years, due to the improvement of living standards, changes in dietary structure and relatively lagging preventive and health care measures, the incidence of fatty liver is still rising, and the age of incidence is getting younger and younger. On the other hand, changes in the social environment have brought about the increase of new synthetic agents and chemicals, and even brought about environmental pollution and public hazards. Like alcoholism, it is the direct cause of chemical liver damage. Liver disease seriously reduces the patient's quality of life and shortens the patient's lifespan.
目前，大多数肝病患者主要是靠药物治疗。肝炎的治疗是一个全方位，精心调理的过程，在此过程中，患者不可避免地要用药，服药，这就要求把药物对人体的副作用降低到极限，最好是不对患者的肝脏产生任何危害，因为，一旦药物有毒副作用，那么这种毒副作用只能依赖病人的肝脏来解除，病人的肝脏本已受到损伤肝功能不健全，如此以来，恶性循环，治肝的同时又伤肝，治肝药品成了双刃剑。西药的毒副作用为疾病的治疗添加了新的困难因素，甚至使患者病上加病。虽然中药与西药相比有得天独厚的优势，但是由于现代工业发展，环境污染严重，中药材在生长过程中，不可避免地受到污染，从而加剧了中药材毒副作用。在治疗过程中，患者大量服药，却终不见效，抑或反倒出现肝功能下降，病情恶化的现象。因此，在治疗肝病的过程中，避免和预防已经有炎症的肝细胞进一步受化学性肝损伤，给肝细胞营造一个良好的生存环境，保护化学性肝损伤就成了辅助治疗慢性肝炎的有效途径。At present, most liver disease patients mainly rely on drug treatment. The treatment of hepatitis is an all-round and meticulously adjusted process. During this process, patients will inevitably need to take medicines. This requires that the side effects of medicines on the human body be reduced to the limit, and it is best not to cause any harm to the patient's liver. , because, once the drug has toxic side effects, the toxic side effects can only be relieved by the patient's liver. The patient's liver has been damaged and the liver function is not perfect. In this way, a vicious cycle, the liver is treated while the liver is damaged, and the liver is treated. Drugs have become a double-edged sword. The toxic and side effects of western medicine have added new difficult factors to the treatment of diseases, and even made patients sicker. Although traditional Chinese medicine has unique advantages compared with western medicine, due to the development of modern industry and serious environmental pollution, Chinese medicinal materials are inevitably polluted during the growth process, which aggravates the toxic and side effects of Chinese medicinal materials. During the course of treatment, the patient took a large amount of medicine, but it did not work in the end, or instead, the liver function declined and the condition worsened. Therefore, in the process of treating liver diseases, avoiding and preventing the already inflamed liver cells from further chemical liver damage, creating a good living environment for liver cells, and protecting chemical liver damage have become an effective way to assist in the treatment of chronic hepatitis. .
本发明的目的是利用生理活性很强的海洋生物提取物科学组方，精制成慢性肝炎治疗过程中和对化学性肝损伤有保护作用的无毒副作用的天然海洋保健食品。The purpose of the present invention is to use the scientific formula of the marine biological extract with strong physiological activity to refine it into a natural marine health food with no toxic and side effects during the treatment of chronic hepatitis and with protective effects on chemical liver damage.
目前国内对化学性肝损伤有保护作用的保健食品，主要是参照中药治疗肝病的机理来选用药食两用的中草药为原料来制备，效果好些的会有类似中药的毒副作用，毒副作用轻一些的则效果不明显。At present, domestic health foods that have a protective effect on chemical liver damage are mainly prepared from Chinese herbal medicines that are both medicinal and edible by referring to the mechanism of traditional Chinese medicine in treating liver diseases. Those with better effects will have similar toxic and side effects as traditional Chinese medicine, and the toxic and side effects are lighter. The effect is not obvious.
以中药材为原料的对化学性肝损伤有保护作用的保健食品，其成份复杂，功效成份不明确，多数是采用性属寒性的中药材，通过降肝火来达到保护肝细胞的目的。Health foods that use Chinese herbal medicines as raw materials to protect against chemical liver damage have complex ingredients and unclear functional ingredients. Most of them use cold Chinese herbal medicines to protect liver cells by reducing liver fire.
采用海洋生物为原料的对化学性肝损伤有保护作用的保健食品极少见到，从海洋生物中分离提取出多种海洋生物活性物，以启动肝脏免疫系统，预防肝纤维化、降毒解毒减轻肝脏负担、清热降肝火，为肝细胞的营造良好的生存环境，以求达到综合高效对化学性肝损伤有保护作用为目的的纯天然海洋保健食品尚未见到。Health food that uses marine organisms as raw materials and has a protective effect on chemical liver damage is rarely seen. A variety of marine biological active substances are isolated and extracted from marine organisms to activate the liver immune system, prevent liver fibrosis, detoxify and detoxify Alleviating liver burden, clearing heat and lowering liver fire, creating a good living environment for liver cells, in order to achieve comprehensive and efficient protection against chemical liver damage, pure natural marine health food has not yet been seen.
发明内容Contents of the invention
本发明的目的在于提供一种见效快、对化学性肝损伤、脂肪肝和其他肝细胞损伤所致的GPT(谷丙转氨酶)升高均有较为明显的食疗效果，而且没有药物毒副作用的对化学性肝损伤有保护作用的保健食品。The object of the present invention is to provide a kind of food therapy that has quick effect, has obvious therapeutic effects on GPT (alanine aminotransferase) elevation caused by chemical liver damage, fatty liver and other liver cell damage, and has no toxic and side effects of drugs. Health food with protective effect on chemical liver injury.
本发明的解决方案是基于对化学性肝损伤和预防肝纤维化的认识及原则，以及对海洋生物活性物的了解，参考现代中西医学和药理学的研究成就，从海洋生物提取物中筛选出多种具有很强的生理活性的海洋生物活性物，科学组方，使其发挥如下效果：1.启动肝脏自身的免疫系统，促使损伤的肝脏恢复和肝细胞的再生；2.平肝潜阳、能清热降肝火，预防肝纤维化，给肝细胞营造良好的生存环境；3.降毒解毒，减轻合成药剂和化学药品对肝细胞的损伤；4.阻碍脂肪的合成和延缓脂肪的吸收，防止脂肪肝的生成，从而减轻肝脏负担。The solution of the present invention is based on the understanding and principle of chemical liver injury and prevention of liver fibrosis, as well as the understanding of marine biological active substances, and with reference to the research achievements of modern Chinese and Western medicine and pharmacology, it is screened from marine biological extracts A variety of marine biological active substances with strong physiological activity, scientifically formulated to make them exert the following effects: 1. Activate the liver's own immune system, promote the recovery of the damaged liver and the regeneration of liver cells; 2. Calm the liver and subdue yang 1. Can clear away heat and lower liver fire, prevent liver fibrosis, and create a good living environment for liver cells; 3. Reduce toxins and detoxify, reduce the damage of synthetic drugs and chemicals to liver cells; 4. Hinder the synthesis of fat and delay the absorption of fat, Prevent the formation of fatty liver, thereby reducing the burden on the liver.
本发明的保健食品由下列重量百分含量的原料制成：Health food of the present invention is made from the raw material of following percentage by weight:
海藻酸钠 5～85％Sodium alginate 5～85%
珍珠层粉 5～85％Pearl layer powder 5～85%
牛黄酸 10～90％。Taurine 10-90%.
制备本发明的保健食品的优选重量配比是：The preferred weight proportion of preparing health food of the present invention is:
海藻酸钠 15～65％Sodium alginate 15～65%
珍珠层粉 15～65％Pearl Layer Powder 15～65%
牛黄酸 20～70％。Taurine 20-70%.
上述用于保护化学性肝损伤的保健食品，通过常规工艺，可以制成药剂学上所说的多种剂型，如胶囊剂、片剂、散剂、冲剂、膏剂或颗粒剂。The above-mentioned health food for protecting chemical liver damage can be made into various dosage forms as mentioned in pharmacy through conventional processes, such as capsules, tablets, powders, granules, ointments or granules.
本发明的一个重要特点是海藻酸钠调节肝脏免疫系统的作用机制，肝纤维化的防治是治疗各种慢性肝病，防治肝硬化形成的一个主要方面，慢性乙型肝炎细胞损伤的主要原因与乙型肝炎病毒所引起的免疫紊乱有关。近期的医学研究发现，慢性迁延型肝炎和慢性活动型肝炎有细胞免疫及体液免疫机能低下的现象。海藻酸钠具有清热、软坚、散结，活血化淤，改善微循环、调节免疫功能和防治肝纤维化的功能。它一方面间接抑制肝细胞内GPT(谷丙转氨酶)地合成，一方面通过减轻肝损伤的病理过程，保护细胞膜结构和功能的完整性，减少GPT的释放。通过激活体内的T淋巴细胞，启动肝脏自身的免疫系统，促使损伤的肝脏恢复和肝细胞的再生，增加肝糖原的合成，提高机体免疫功能，从而起到保护肝细胞的作用。An important feature of the present invention is that sodium alginate regulates the action mechanism of the liver immune system. The prevention and treatment of liver fibrosis is a main aspect in the treatment of various chronic liver diseases and the formation of liver cirrhosis. The main cause of chronic hepatitis B cell damage is related to that of B immune disorders caused by hepatitis virus. Recent medical research has found that chronic persistent hepatitis and chronic active hepatitis have the phenomenon of hypofunction of cellular immunity and humoral immunity. Sodium alginate has the functions of clearing away heat, softening hardness, dispelling stagnation, promoting blood circulation and removing stasis, improving microcirculation, regulating immune function and preventing liver fibrosis. On the one hand, it indirectly inhibits the synthesis of GPT (alanine aminotransferase) in liver cells; on the other hand, it reduces the release of GPT by alleviating the pathological process of liver injury, protecting the integrity of cell membrane structure and function. By activating T lymphocytes in the body, starting the liver's own immune system, promoting the recovery of the damaged liver and the regeneration of liver cells, increasing the synthesis of liver glycogen, improving the body's immune function, and thus protecting the liver cells.
本发明的另一个重要特点是珍珠层粉降肝火的功能。肝病患者，肝热火气盛，情绪以及热性食物均能加重肝细胞的损伤。珍珠层粉性属咸、寒，归肝、心经。经过常温、物理处理过的珍珠层粉，具有平肝潜阳、定惊明目的作用，用于头痛眩晕，烦躁失眠，肝热目赤，肝虚目昏。能清热降肝火，给肝细胞营造良好的生存环境。Another important feature of the present invention is the function of the nacre powder for reducing liver fire. For patients with liver disease, the liver is hot and angry, and emotions and hot food can aggravate the damage of liver cells. Nacre powder is salty and cold in nature, and belongs to the liver and heart channels. The pearl layer powder that has been treated at room temperature has the functions of calming the liver and suppressing yang, calming convulsions and improving eyesight. It can clear away heat and lower liver fire, and create a good living environment for liver cells.
本发明的另外一个重要特点是该保健食品中的牛黄酸是人及动物体内的一种含硫氨基酸，对维持人和动物正常生理功能具有重要作用。酒精、合成药剂和化学药品，都会有不同程度的破坏生物膜结构和功能，导致肝细胞坏死，使细胞内转氨酶释放至血液引起GPT活性升高。GPT是反映肝脏溶酶体稳定性或损伤程度的重要指标之一，CCl4(四氯化碳)是损伤肝细胞的化学物质，肝细胞接触CCl4后内部合成牛黄酸能力提高，牛黄酸可以降低GPT的释放，从而起到保护肝细胞的作用。牛黄酸具有清热消炎，降低许多药物和其他有毒性物质的毒性的功能，对肝脏溶酶体膜有稳定作用。Another important feature of the present invention is that the taurine in the health food is a sulfur-containing amino acid in human and animal bodies, and plays an important role in maintaining normal physiological functions of human and animals. Alcohol, synthetic agents and chemicals will destroy the structure and function of the biofilm to varying degrees, lead to necrosis of liver cells, and release intracellular transaminases into the blood to increase the activity of GPT. GPT is one of the important indicators reflecting the stability or damage of liver lysosomes. CCl 4 (carbon tetrachloride) is a chemical substance that damages liver cells. After liver cells are exposed to CCl 4 , their internal synthesis of taurine is improved. Taurine can Reduce the release of GPT, thereby protecting the liver cells. Taurine has the functions of clearing heat and reducing inflammation, reducing the toxicity of many drugs and other toxic substances, and stabilizing the liver lysosome membrane.
另外，海藻酸钠是高纯度膳食纤维，吸水膨润后形成粘稠度很高的胶体溶液，食物糊因摄入海藻酸钠后粘度上升，因而延长食物糊在胃内的滞留时间，延缓了脂肪类的消化吸收过程。其次是具有抑制胰脂肪酶的活性，阻止脂肪被分解为脂肪酸和β-单酸甘油酯而被吸收，从而减少机体对脂肪的合成及延缓机体对脂肪的吸收，防止脂肪肝的生成，减轻肝脏负担。In addition, sodium alginate is a high-purity dietary fiber. It absorbs water and swells to form a highly viscous colloidal solution. The viscosity of food paste increases after ingestion of sodium alginate, thus prolonging the residence time of food paste in the stomach and delaying Digestion and absorption of fats. Secondly, it has the activity of inhibiting pancreatic lipase, preventing fat from being decomposed into fatty acids and β-monoglycerides and being absorbed, thereby reducing the body's synthesis of fat and delaying the body's absorption of fat, preventing the formation of fatty liver, and reducing liver damage. burden.
另外，本发明的保健食品功效成份明确，质量稳定，易于控制。In addition, the health food of the invention has clear functional components, stable quality and easy control.
本发明的保健食品通过功能实验，结果表明具有下述优点：Health food of the present invention passes function test, and the result shows to have following advantage:
1、本发明选用海洋生物提取物为原料，组分少，味清淡，食用方便。天然无副作用，符合国家食品卫生法规定。1. The present invention selects marine biological extracts as raw materials, has few components, light taste, and is convenient to eat. Natural without side effects, in line with the provisions of the National Food Sanitation Law.
2、本发明的保健食品对各种化学性肝损伤和其他肝细胞损伤所致的GPT升高均有较为明显的功效，而且没有药物的毒副作用。2. The health food of the present invention has obvious effects on the increase of GPT caused by various chemical liver injuries and other liver cell injuries, and has no toxic and side effects of drugs.
3、本发明的保健食品可以在不停药的情况下服用，也可以单独服用。3. The health food of the present invention can be taken without stopping the medicine, or taken alone.
4、本发明的保健食品对肝炎的康复者有较好的辅助食疗作用。4. The health food of the present invention has a better auxiliary dietary therapy effect on the recovered patients of hepatitis.
5、本发明的保健食品具有软坚散结、阻碍脂肪吸收防止脂肪肝生成的效果。5. The health food of the present invention has the effects of softening and resolving hard masses, hindering fat absorption and preventing fatty liver formation.
下面结合具体实施方式和功能实验结果对本发明作进一步的说明。The present invention will be further described below in conjunction with specific implementation methods and functional experiment results.
具体实施方式Detailed ways
实施例1Example 1
本发明的保健食品由下列重量百分含量的原料制成：Health food of the present invention is made from the raw material of following percentage by weight:
海藻酸钠 10％Sodium Alginate 10%
珍珠层粉 10％Pearl layer powder 10%
牛黄酸 80％。Taurine 80%.
将上述组分制成胶囊的生产方法是：(1)分别将原料干燥、粉碎至80目以上的细度；(2)将上述粉剂组分按比例混合配制后，使用伽玛射线辅照，进行灭菌、消毒，产品的实际吸收剂量为5.0KGY，按填充胶囊工序填充胶囊，装瓶，包装。The production method of making the above components into capsules is: (1) drying and pulverizing the raw materials to a fineness above 80 mesh; (2) mixing and preparing the above powder components in proportion, using gamma ray assisted irradiation, Sterilize and disinfect, the actual absorbed dose of the product is 5.0KGY, fill the capsules according to the capsule filling process, bottle and pack.
实施例2Example 2
本发明的保健食品由下列重量百分含量的原料制成：Health food of the present invention is made from the raw material of following percentage by weight:
海藻酸钠 20％Sodium Alginate 20%
珍珠层粉 60％Pearl layer powder 60%
牛黄酸 20％。Taurine 20%.
将上述组分制成冲剂的生产方法是：(1)分别将原料干燥、粉碎至80目以上的细度；(2)将上述粉剂组分按比例混合配制后，使用伽玛射线辅照，进行灭菌、消毒，产品的实际吸收剂量为5.0KGY，按冲剂工序制备冲剂，包装。The production method of making the above components into granules is: (1) drying and pulverizing the raw materials to a fineness of more than 80 meshes; (2) mixing and preparing the above powder components in proportion, using gamma ray assisted irradiation, Carry out sterilization, disinfection, the actual absorbed dosage of product is 5.0KGY, prepare granule according to granule procedure, pack.
实施例3Example 3
本发明的保健食品由下列重量百分含量的原料制成：Health food of the present invention is made from the raw material of following percentage by weight:
海藻酸钠 60％Sodium Alginate 60%
珍珠层粉 20％Pearl layer powder 20%
牛黄酸 20％。Taurine 20%.
将上述组分制成片剂的生产方法是：(1)分别将原料干燥、粉碎至80目以上的细度；(2)将上述粉剂组分按比例混合配制后，使用伽玛射线辅照，进行灭菌、消毒，产品的实际吸收剂量为5.0KGY，按制片工序制备片剂，包装。The production method of making the above components into tablets is as follows: (1) drying and pulverizing the raw materials to a fineness above 80 mesh; (2) mixing and preparing the above powder components in proportion, using gamma ray assisted irradiation , sterilized and disinfected, the actual absorbed dose of the product is 5.0KGY, and tablets are prepared and packed according to the tablet-making process.
功能实验结果Functional Experiment Results
本发明对四氯化碳中毒性小白鼠有抑制受损肝组织的脂质过氧化作用，能明显抑制由于四氯化碳所引起的血清谷丙转氨酶活力的升高。在本发明的作用下残留的肝脏核分裂相数目明显增多，再生度高于对照组，说明对肝脏细胞有促进再生作用。本发明能减轻实验中毒性小白鼠肝组织的病理损伤，促使损伤的肝脏恢复和肝细胞的再生，增加肝糖原的合成，并提高机体的免疫功能。The invention has the effect of inhibiting lipid peroxidation of damaged liver tissue in mice poisoned by carbon tetrachloride, and can obviously inhibit the increase of serum alanine aminotransferase activity caused by carbon tetrachloride. Under the action of the present invention, the number of residual hepatic mitotic phases is significantly increased, and the degree of regeneration is higher than that of the control group, which shows that it can promote the regeneration of liver cells. The invention can alleviate the pathological damage of the liver tissue of the toxic mice in the experiment, promote the recovery of the damaged liver and the regeneration of liver cells, increase the synthesis of liver glycogen, and improve the immune function of the body.
Claims (3)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100333975A CN1301070C (en) | 2005-03-07 | 2005-03-07 | Heath-caring product having protecting function for chemical liver injury |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100333975A CN1301070C (en) | 2005-03-07 | 2005-03-07 | Heath-caring product having protecting function for chemical liver injury |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1663449A true CN1663449A (en) | 2005-09-07 |
| CN1301070C CN1301070C (en) | 2007-02-21 |
Family
ID=35034898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100333975A Expired - Fee Related CN1301070C (en) | 2005-03-07 | 2005-03-07 | Heath-caring product having protecting function for chemical liver injury |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1301070C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108617779A (en) * | 2018-03-29 | 2018-10-09 | 新疆旺源生物科技集团有限公司 | A kind of hunchbacked milk composition having auxiliary protection function to chemical damage |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1060340C (en) * | 1994-05-23 | 2001-01-10 | 中国科学院动物研究所 | Marine full-pearl shell powder and preparing process thereof |
| CN1120003C (en) * | 2000-06-20 | 2003-09-03 | 罗世江 | Water-soluble pearl component and its preparing process |
| CN1476782A (en) * | 2002-08-20 | 2004-02-25 | 北京京港耀新生物技术开发有限公司 | Preparation process of complete-component pearl product |
| CN1456097A (en) * | 2003-04-26 | 2003-11-19 | 李扬远 | Functional marine food and producing method thereof |
-
2005
- 2005-03-07 CN CNB2005100333975A patent/CN1301070C/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108617779A (en) * | 2018-03-29 | 2018-10-09 | 新疆旺源生物科技集团有限公司 | A kind of hunchbacked milk composition having auxiliary protection function to chemical damage |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1301070C (en) | 2007-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101590168B (en) | Traditional Chinese medicine combination for treating gout and preparation method thereof | |
| CN101590184B (en) | Traditional Chinese medicine combination for treating gout and preparation method thereof | |
| CN103356867B (en) | A medicine for clearing heat, detoxifying, reducing inflammation and relieving pain | |
| CN103432551B (en) | Externally applied medicine for treating scapulohumeral periarthritis, radiohumeral bursitis and inexplicable ostalgia | |
| CN1256969C (en) | Chinese medicine for treating bone disease and its preparation | |
| CN101590169B (en) | Traditional Chinese medicine combination for treating gout and preparation method thereof | |
| CN101590167B (en) | Traditional Chinese medicine combination for treating gout and preparation method thereof | |
| CN1663449A (en) | A health food with protective effect on chemical liver damage | |
| CN104474528B (en) | Medications for Drainage and Detoxification | |
| CN101590166B (en) | Traditional Chinese medicine combination for treating gout and preparation method thereof | |
| CN1899531A (en) | Medicine for preventing and treating chicken kidney swelling disease | |
| CN104940291A (en) | Composition for preventing and treating honeybee microsporidiosis and use thereof | |
| CN1631403A (en) | A kind of pharmaceutical composition for treating constipation and its preparation and preparation method | |
| CN108404040A (en) | The application of drug containing Turmeric P.E and preparation method thereof and Turmeric P.E in preparing the drug for treatment of arthritis | |
| CN102824414A (en) | Medicinal tea used for treating constipation | |
| CN101700258A (en) | Drug for curing herpes zoster | |
| CN1943768A (en) | A Chinese traditional medicine for treatment of hemorrhoid, anal fistula and anal fissure and their preparation methods | |
| KR20010026947A (en) | Sub-food manufecturing method | |
| CN1236809C (en) | Trauma treating medicament and method for making same | |
| CN1824103A (en) | External use medicine for treating knocks and falls and bone joining | |
| CN1557415A (en) | A kind of pharmaceutical preparation for treating liver and gallbladder disease and preparation method thereof | |
| CN103705618B (en) | Treat beriberic medicine | |
| CN100531763C (en) | A kind of medicinal wine for dispelling dampness and analgesic | |
| CN1768798A (en) | Medicine for promoting qi circulation, resolving food retention, benefiting stomach and stopping pain and preparation process thereof | |
| CN1299755C (en) | Cinnamon compound medicine, and its preparing method and use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070221 |